When I say "historic" for
BMY
I'm not talking ATH but the stock's encroaching on an area that has been tested 3 times being rejected each time. This is the 236 fib area using 2016's high as the top anchor. It's been 5 years since BMY traded well above this area. But with the way attention is being placed on immunotherapy stocks, it could be something to keep in mind for BMY longs.
"Both Bristol-Myers and Novartis recently gave updates on new FDA updates. Novartis’ NIS793 gained FDA Orphan Drug Designation, while Bristol-Myers’ recent earnings update revealed strong sales figures from its lead cancer drug, Opdivo...B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment. While things are still in the very early stages for B7 molecules, as a whole, early research is also finding new potential for targeted cancer treatments. For instance, Merck’s (NYSE:
MRK
) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment."
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
BMY
I'm not talking ATH but the stock's encroaching on an area that has been tested 3 times being rejected each time. This is the 236 fib area using 2016's high as the top anchor. It's been 5 years since BMY traded well above this area. But with the way attention is being placed on immunotherapy stocks, it could be something to keep in mind for BMY longs. "Both Bristol-Myers and Novartis recently gave updates on new FDA updates. Novartis’ NIS793 gained FDA Orphan Drug Designation, while Bristol-Myers’ recent earnings update revealed strong sales figures from its lead cancer drug, Opdivo...B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment. While things are still in the very early stages for B7 molecules, as a whole, early research is also finding new potential for targeted cancer treatments. For instance, Merck’s (NYSE:
MRK
) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment." Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio